Монотерапия артериальной гипертензии: конец главы или продолжение следует?

1. Agabiti-Rosei E, Ambrosioni E, Fimardi G et al. Perindopril versus captopril: efficacy and acceptability in an Italian multicenter trial. Am J Med 1992; 92: 79–83.
2. Grandi AM, Venco A, Barzizza F et al. Doubleblind comparison of perindopril and captopril in hypertension: effects on left ventricular morphology and function. Hypertension 1991; 4: 516–20.
3. Anan F, Takahashi N, Ooie T et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 2005; 61: 353–9.
4. Chen JMH, Heran BS, Wright JM et al. Blood pressure lowering efficacy of diuretics as secondline therapy for primary hypertension. Cochrane Database Syst Rev 2009; 4:CD007187.
5. Deary A, Schumann A, Murfet H et al. Doubleblind, placebocontrolled crossover comparison of five classes of antihypertensive drugs. J Hypertension 2002; 20: 771–77.
6. Dickerson JEC, Hingorani AD, Ashby MJ et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008.
7. Egan B, Basile J, Rehman S et al. Plasma renin testguided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial.  Am J Hypertens 2009; 22: 792–801.
8. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension: lesson XVI: how to choose the correct drug treatment for each hypertensive patient using a plasma reninbased method with volumevasoconstriction analysis. Am J Hypertens 2001; 14: 491–503.
9. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
10. Lees KR, Reid JL, Scott MG et al. Captopril versus perindopril:a double blind study in essential hypertension. Hypertension 1989; 3: 17–22.
11. Materson BJ, Reda DJ, Cushman WC et al. Singledrug therapy for hypertension in men. a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 9–14.
12. Materson BJ, Reda DJ, Preston RA et al. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Arch Intern Med 1995; 155: 17–57.
13. Saito I, Saruta T. Hypertens Res 2006; 29: 789–96.
14. Schmieder R, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: metaanalysis of randomized studies. JAMA 1996; 275: 1507–13.
15. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009; 22: 112–21.
16. Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high and lowbaseline PRA levels, respectively. Am J Hypertens 2009; 22: 954–57.
17. Staessen, JA, Wang, JG, Thijs, L. Cardiovascular prevention and blood pressure reduction. J Hypertens 2003; 21: 10–55.
18. Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomised trials. BMJ 2008; 336: 11–21.
19. Villatico S, Campbell V, Rizzo F et al. Antihypertensive therapy with losartan and fosinopril: efficacy in left ventricular hypertrophy regression. Am J Hypertens 1998; 11: 125A.
20. Yoshinara K, Sarut T, Abe K et al. Clinical evalution of monotherapy with perindopril, an ACE inhibitor in the treatment of essential hypertension: doubleblind parallel comparison with enalapril Rinsho Iyaku. 1997; 13: 4259–97.

С.В.Недогода 

Кафедра терапии и эндокринологии ФУВ, Волгоградский государственный медицинский университет